<DOC>
	<DOCNO>NCT02669875</DOCNO>
	<brief_summary>Portal hypertension ( increase blood pressure portal vein carry blood intestine spleen liver ) underlie serious complication liver cirrhosis . This randomise placebo control study people liver cirrhosis evaluate acute effect serelaxin ( RLX030 ) infusion portal hypertension liver blood flow .</brief_summary>
	<brief_title>Serelaxin To Lower Portal Pressure</brief_title>
	<detailed_description>This study investigate effect investigational drug serelaxin ( recombinant form peptide human relaxin-2 ) portal hypertension patient liver cirrhosis . The investigator measure portal pressure hepatic venous pressure gradient ( HVPG ) hepatic blood flow indocyanine green ( ICG ) clearance evaluate potential benefit drug . In recently complete small exploratory open-label phase 2 study ( EudraCT . 201200023626 , NCT01640964 ) , Part B demonstrate serelaxin lower portal pressure .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<criteria>1 . Male female adult subject 18 year age 2 . Able provide write informed consent able understand willing comply requirement study 3 . Clinical imagingdiagnosed biopsyproven liver cirrhosis aetiology 4 . Evidence portal hypertension either image previous endoscopy 5 . Patients large/grade 3 varix identify endoscopy within 6 month screen must endoscopic band ligation programme time study entry 6 . Suspected hepatic venous pressure gradient ( HVPG ) â‰¥10 mmHg baseline 1 . Pregnancy breast feed 2 . Severe liver failure define one following : Prothrombin activity &lt; 40 % , Bilirubin &gt; 5 mg/dL ( 85umol/L ) , hepatic encephalopathy &gt; grade I 3 . Presence noncontrolled clinically significant disease could affect study outcome would place patient undue risk 4 . Hepatocellular carcinoma 5 . Portal vein thrombosis 6 . Previous surgical shunt TIPSS 7 . Current use betablockers nitrate , drug therapy know influence portal pressure ( diuretic permit provided patient stable dose least 30 day ) 8 . History drug alcohol abuse within 1 month enrolment 9 . Arterial hypotension ( sit Systolic Blood Pressure &lt; 100 mmHg ) 10 . Use investigational drug within 5 halflives enrolment , within 30 days/until expect pharmacodynamic effect return baseline , whichever longer 11 . Long QT syndrome 12 . Documented hypersensitivity intravenous contrast agent and/or iodine 13 . Severe renal impairment ( eGFR &lt; 30 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>